Indobufen and PAD4 inhibition attenuate atherosclerosis via suppression of platelet-induced neutrophil extracellular traps

Background Atherosclerosis (AS) is a chronic inflammatory disease underpinning major cardiovascular events. Neutrophil extracellular traps (NETs) contribute to AS progression, but whether antiplatelet therapy with indobufen affects NETs remains unknown. This study investigates the effects and mechanisms of indobufen and a novel PAD4 inhibitor on NET formation and AS pathogenesis. Methods Circulating NETs markers were quantified in patients with coronary heart disease. In vitro, we assessed the impact of NETs on endothelial cell apoptosis and signaling, and examined the role of activated platelets in inducing NETosis. An AS mouse model was used to evaluate the therapeutic effects of indobufen and the PAD4 inhibitor HH9429, alone or in combination, on plaque burden and NET-related mechanisms. Results NET levels were elevated in patients with CHD. NETs directly induced endothelial apoptosis via the JAK2-STAT3 pathway. Mechanistically, activated platelets triggered NET release through HMGB1, a process significantly attenuated by indobufen. In vivo, both indobufen and HH9429 reduced NET formation and atherosclerotic lesions, and their combination produced enhanced therapeutic effects by suppressing the HMGB1-RAGE axis and NET-associated inflammation. Conclusions Indobufen limits NETs formation by inhibiting platelet-derived HMGB1. Combining indobufen with a PAD4 inhibitor amplifies these protective effects, highlighting a potential dual-target strategy against NET-mediated pathology in AS. These findings provide new insights into platelet-NET crosstalk and suggest a promising therapeutic approach.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-11-19
DOI
https://doi.org/10.1186/s12916-026-05425-3
Primary Topic
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Indobufen and PAD4 inhibition attenuate atherosclerosis via suppression of platelet-induced neutrophil extracellular traps

辛艳飞, Yutian Mi, Dengke Bao, Yu Jia et al.
BMC Medicine
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
article

Indobufen and PAD4 inhibition attenuate atherosclerosis via suppression of platelet-induced neutrophil extracellular traps

辛艳飞, Yutian Mi, Dengke Bao, Yu Jia, Jing Zhao, Mingde Xia, Zhengwei Guo, Zhiming Song, 邵瑾瑾, Fangqi An, Menghan Shi, Shuangyang Xue, Ang Zhao, Shuwen Bai, Chenhao Liu, Yanming Wang, Siyuan Huo
article en

Abstract

Background Atherosclerosis (AS) is a chronic inflammatory disease underpinning major cardiovascular events. Neutrophil extracellular traps (NETs) contribute to AS progression, but whether antiplatelet therapy with indobufen affects NETs remains unknown. This study investigates the effects and mechanisms of indobufen and a novel PAD4 inhibitor on NET formation and AS pathogenesis. Methods Circulating NETs markers were quantified in patients with coronary heart disease. In vitro, we assessed the impact of NETs on endothelial cell apoptosis and signaling, and examined the role of activated platelets in inducing NETosis. An AS mouse model was used to evaluate the therapeutic effects of indobufen and the PAD4 inhibitor HH9429, alone or in combination, on plaque burden and NET-related mechanisms. Results NET levels were elevated in patients with CHD. NETs directly induced endothelial apoptosis via the JAK2-STAT3 pathway. Mechanistically, activated platelets triggered NET release through HMGB1, a process significantly attenuated by indobufen. In vivo, both indobufen and HH9429 reduced NET formation and atherosclerotic lesions, and their combination produced enhanced therapeutic effects by suppressing the HMGB1-RAGE axis and NET-associated inflammation. Conclusions Indobufen limits NETs formation by inhibiting platelet-derived HMGB1. Combining indobufen with a PAD4 inhibitor amplifies these protective effects, highlighting a potential dual-target strategy against NET-mediated pathology in AS. These findings provide new insights into platelet-NET crosstalk and suggest a promising therapeutic approach.

BMC Medicine
Henan University (CN), First Affiliated Hospital of Henan University (CN)
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon